Modulation of Oral Morphine Antinociceptive Tolerance and Naloxone-Precipitated Withdrawal Signs by Oral
|
|
- Hector Randall Hall
- 5 years ago
- Views:
Transcription
1 /03/ $7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 305, No. 3 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 46870/ JPET 305: , 2003 Printed in U.S.A. Modulation of Oral Morphine Antinociceptive Tolerance and Naloxone-Precipitated Withdrawal Signs by Oral 9 -Tetrahydrocannabinol DIANA L. CICHEWICZ and SANDRA P. WELCH Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia Received November 21, 2002; accepted February 3, 2003 ABSTRACT Previous studies have demonstrated a functional interaction between cannabinoid and opioid systems in the development and expression of morphine tolerance and dependence. In these experiments, we examined the effect of a low oral dose of 9 -tetrahydrocannabinol ( 9 -THC) on the development of oral morphine tolerance and the expression of naloxone-precipitated morphine withdrawal signs of jumping and diarrhea in ICR mice. Chronic treatment with high-dose oral morphine produced a 3.12-fold antinociceptive tolerance. Tolerance to morphine was prevented in groups receiving a daily cotreatment with a nonanalgetic dose (20 mg/kg p.o.) of 9 -THC, except when challenged with a very high dose of morphine. The chronic coadministration of low-dose 9 -THC also reduced The clinical use of morphine for long periods of time is limited by its propensity to cause tolerance and physical dependence after repeated administration. To overcome tolerance to the analgesic effects of morphine, higher doses are necessary for adequate pain relief but are often accompanied by undesirable side effects such as constipation, nausea, and respiratory depression (Ellison, 1993). Morphine tolerance has been developed in rodent models using subcutaneously implanted morphine pellets (Cicero and Meyer, 1973; Bhargava, 1978), but little is known about tolerance to oral doses of morphine in mice. Mao et al. (1996) observed a decrease in antinociception produced by oral morphine in rats as measured by the tail-flick test over a period of several days. Our laboratory and others have shown that combinations of cannabinoids with morphine profoundly enhance morphine-induced analgesia. 9 -THC at a nonanalgetic dose administered p.o. to mice significantly enhances the potency of This work was supported by National Institute on Drug Abuse Grants DA-07027, DA-05274, and K02-DA Article, publication date, and citation information can be found at DOI: /jpet naloxone-precipitated (1 mg/kg s.c.) platform jumping by 50% but did not reduce diarrhea. In separate experiments, mice treated chronically with high-dose morphine p.o. were not cross-tolerant to 9 -THC; in fact, these morphine-tolerant mice were more sensitive to the acute antinociceptive effects of 9 -THC. 9 -THC (20 mg/kg p.o.) also reduced naloxone-precipitated jumping but not diarrhea when administered acutely to morphine-tolerant mice. These results represent the first evidence that oral morphine tolerance and dependence can be circumvented by coadministration of a nonanalgetic dose of 9 -THC p.o. In summary, cotreatment with a combination of morphine and 9 -THC may prove clinically beneficial in that long-term morphine efficacy is maintained. opioids such as morphine and codeine (Smith et al., 1998; Cichewicz et al., 1999). This enhancement is theorized to be due to a combination of morphine s direct effects on the -opioid receptor and the effect of endogenous opioids whose release is stimulated by 9 -THC (Smith et al., 1994; Pugh et al., 1996). In addition, the CB1 cannabinoid receptor and -opioid receptor have been found to be colocalized in areas important for the expression of morphine abstinence: nucleus accumbens, septum, striatum, periaqueductal gray area, and amygdaloid nucleus (Navarro et al., 1998). Thus, we hypothesize that 9 -THC might alter the expression of morphine antinociceptive tolerance and/or dependence. 9 -THC reduces naloxone-precipitated withdrawal in morphine-dependent rats and mice (Hine et al., 1975; Bhargava, 1976). The endogenous cannabinoid anandamide also decreases naloxone-precipitated morphine withdrawal (Vela et al., 1995). Furthermore, several studies indicate that the morphine withdrawal syndrome is markedly decreased in CB1-receptor knockout mice (Ledent et al., 1999; Lichtman et al., 2001). Blockade of the CB1 receptor by the antagonist SR A has been shown to precipitate morphine withdrawal signs such as weight loss, teeth chattering, and diar- ABBREVIATIONS: 9 -THC, 9 -tetrahydrocannabinol; SR A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboximide hydrochloride; % MPE, percentage of maximum possible effect; CL, confidence limits; ANOVA, analysis of variance; DAMGO, [D-Ala 2,N-Me-Phe 4,Gly 5 -ol]-enkephalin; NMDA, N-methyl-D-aspartate; MK-801, dizocilpine maleate. 812
2 Modulation of Morphine Tolerance and Dependence by 9 -THC 813 rhea in dependent rats (Navarro et al., 1998). Recently, acute administration of 9 -THC blocked some signs of morphine withdrawal in mice (paw tremors and head shakes), but not jumping or diarrhea (Lichtman et al., 2001). These findings suggest a role of the endogenous cannabinoid system in opioid dependence. However, similar studies have never been performed using orally administered cannabinoids. An oral preparation of 9 -THC (Marinol) is approved in the United States for several indications including cachexia and emesis. Our study of orally administered 9 -THC for prevention of tolerance or dependence to morphine was designed to provide a potential new indication for Marinol, based on our previous data with 9 -THC/morphine combinations. In the present study, we investigated the effect of an orally administered nonanalgetic dose of 9 -THC in altering the behavioral expression of oral morphine tolerance and physical dependence by examining antinociception and naloxoneprecipitated withdrawal signs (platform jumping and diarrhea). In addition to examining the effects of acutely administered 9 -THC on the expression of morphine abstinence, we also evaluated the ability of the low-dose 9 -THC coadministered with morphine for 7 days to prevent development of tolerance to and/or dependence on morphine. A clinical extrapolation for such findings would be important, since lower doses of drugs are desirable to maximize pain relief but minimize side effects and drug tolerance. Materials and Methods Animals. Male ICR mice (Harlan, Indianapolis, IN) weighing 20 to 24 g were housed three per cage in an animal care facility maintained at 22 2 C on a 12-h light/dark cycle. Food and water were available ad libitum. Chronic drug administration was done in the animal care facility, and then the mice were brought to the test room 12 h before testing to allow acclimation and recovery from transport and handling. All experiments were conducted in accordance with guidelines from the Institutional Animal Care and Use Committee at Virginia Commonwealth University. Chronic Drug Administration. Mice were administered distilled water vehicle or morphine by oral gavage in a ramped paradigm twice daily for 7 days (200 mg/kg, days 1 2; 300 mg/kg, days 3 7). This paradigm was used to prevent toxicity at the beginning of the study from the high 300 mg/kg morphine dose that produces a robust morphine tolerance. To confirm tolerance to morphine, groups of six mice treated with the above paradigm were challenged 12 h after the last chronic administration with varying doses of morphine p.o. (one dose per group) and tested 30 min later in the tail-flick test to obtain dose-response curves for morphine. Prevention of Morphine Tolerance and Dependence. For chronic combination studies, separate groups of six mice were administered a dose of 20 mg/kg 9 -THC p.o., 15 min before each morphine administration as described above (twice daily for 7 days). This dose of 9 -THC was previously determined to produce less than 20% antinociceptive effect in acute dose-response studies (Fig. 1). In addition, previous work in the laboratory has determined that this dose of 9 -THC given orally twice daily for 7 days does not yield antinociceptive tolerance (D. L. Cichewicz, unpublished observations). On the test day, the mice were challenged 12 h after the last chronic administration with varying doses of morphine p.o. (one dose per group) and tested 30 min later in the tail-flick test to obtain a dose-response curve for morphine. Reversal of Morphine Tolerance and Dependence. In the studies of the acute effects of 9 -THC on morphine tolerance and withdrawal, separate groups of six mice were treated with the chronic morphine paradigm described earlier (200 mg/kg, days 1 2; Fig. 1. Dose-response analysis of 9 -THC administered acutely to mice. Note that a 20 mg/kg dose produces less than 20% MPE and therefore was chosen as our low dose for subsequent experiments. Mice were administered various doses of 9 -THC p.o. and tested 30 min later in the tail-flick test for antinociception. Each data point represents an average % MPE S.E.M. of six mice. 300 mg/kg, days 3 7) twice daily. The mice were then administered various doses of 9 -THC p.o. 12 h after their last chronic morphine administration and tested 30 min later in the tail-flick test for antinociception. Evaluation of Physical Dependence to Morphine. Separate groups of six mice were challenged with 1 mg/kg naloxone s.c. 2 h after the last drug administration. Immediately after naloxone injection, each mouse was placed on an elevated pedestal, with a platform 1 foot in height 4 inches in diameter, and observed for 10 min for the presence or absence of jumping and diarrhea, two signs indicative of naloxone-precipitated morphine withdrawal (Way et al., 1969). Data are presented as the percentage of mice (in a group of six) that exhibited platform jumping or diarrhea. Analgesic Assay. The tail-flick heat latency test for antinociception was designed by D Amour and Smith (1941). A radiant heat light focused on the tail of the mouse automatically shuts off when the mouse reflexively flicks its tail out of the light beam. Baseline tail-flick latencies were determined prior to drug administration on the test day and were between 2 and 4 s. During drug testing, a cutoff time of 10 s was employed to prevent damage to the tail. Antinociception was quantified using the percentage of maximum possible effect (% MPE) calculated as developed by Harris and Pierson (1964) as follows: % MPE [(test baseline)/(10 baseline)] 100. A mean % MPE value was determined for each group of six mice. Statistical Analysis. ED 50 values, potency ratios, and 95% confidence limits (CL) for morphine dose-response curves were determined using unweighted least-squares linear regression as modified from procedures 5 and 8 described by Tallarida and Murray (1987). Comparisons between groups in the dependence studies were performed using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer post hoc test for between-group comparisons. Statistical significance was set at p Drugs. 9 -THC and morphine were obtained from the National Institute on Drug Abuse (Bethesda, MD). 9 -THC was prepared in 1:1:18 (ethanol/emulphor/isotonic saline), and morphine was dissolved in distilled water. Results 9 -THC Dose-Response Curve. To determine a nonanalgetic dose of 9 -THC for use in combination studies, we performed an acute dose-response analysis (Fig. 1). Based on the data, we chose a 20 mg/kg dose, which produces less than 20% MPE, as our low inactive dose to combine with morphine in further studies. This dose has been reported in the literature as the most effective for enhancement of morphine an-
3 814 Cichewicz and Welch TABLE 1 Morphine ED 50 values after 7-day treatment with vehicle, morphine, or a combination of 9 -THC and morphine Mice in groups of six were administered drugs twice daily for 7 days and tested for morphine antinociception 12 h after the last drug administration. In the combination group, 9 -THC was administered 15 min prior to morphine. ED 50 values were calculated from at least three doses of morphine. Potency ratio indicates shift between vehicle and drug-treated groups. Treatment Morphine ED 50 (95% CL) Potency Ratio mg/kg Vehicle (distilled water) 40.3 ( ) Morphine a ( )* 3.12 Morphine a 20 mg/kg 9 -THC 48.5 ( ) 1.28 a Represents a 200 to 300 mg/kg p.o. regimen as described under Materials and Methods. * Significantly different from vehicle ED 50 value. Fig. 3. Effects of 9 -THC on naloxone-precipitated morphine withdrawal platform jumping. Mice were treated chronically with either distilled water vehicle, morphine (200 mg/kg p.o., days 1 2; 300 mg/kg p.o., days 3 7), or morphine plus 20 mg/kg 9 -THC p.o. twice daily for 7 days. Naloxone (1 mg/kg s.c.) was injected 2 h after the last drug administration, and the mice were immediately placed on platforms and observed for 10 min. Results are presented as the percentage of mice in each group of six that jumped from the platform., significantly different from vehicletreated group (p 0.05). #, significantly different from morphine-treated group (p 0.05), ANOVA and Tukey-Kramer post hoc test. Fig. 2. A dose of 20 mg/kg 9 -THC p.o. attenuates the development of oral morphine tolerance. Mice received distilled water vehicle, morphine (200 mg/kg p.o., days 1 2; 300 mg/kg p.o., days 3 7), or morphine plus 20 mg/kg 9 -THC p.o. twice daily for 7 days. At 12 h after the last drug administration, various doses of morphine were administered p.o. and the mice were tested 30 min later in the tail-flick test. Each data point represents an average % MPE S.E.M. of six mice. algesia without producing intrinsic antinociception (Smith et al., 1998; Cichewicz et al., 1999). Effects of Chronic 9 -THC on the Prevention of Morphine Tolerance. Mice were treated twice daily for 7 days with either distilled water vehicle p.o. or morphine p.o. (200 mg/kg on days 1 2; 300 mg/kg on days 3 7). Administration of morphine p.o. on the test day produced a dose-response relationship in chronic vehicle-treated mice (ED mg/kg; Fig. 2). In morphine-tolerant mice, the dose-response curve of morphine was shifted to the right 3.12-fold, as determined by the ED 50 values (Table 1). When 9 -THC was administered concurrently with morphine for 7 days, THC prevented the development of morphine tolerance. Although the curves showed a trend toward convergence at the highest dose of morphine tested, the ED 50 value of 48.5 mg/kg (95% CL ) for the combination was similar to that of the vehicle-treated group, and the 95% CL overlapped, indicating that the vehicle curve and the combination curve were not significantly different. Thus, the addition of 9 -THC prevented the development of morphine tolerance in these animals. Effect of Chronic 9 -THC on the Prevention of Physical Dependence to Morphine. To evaluate whether 9 - THC would alter the expression of behavioral withdrawal signs associated with morphine dependence, mice were treated twice daily for 7 days with orally administered distilled water vehicle, morphine alone, or morphine in combination with a low 20 mg/kg dose of 9 -THC as described earlier. On the test day, the mice were challenged with 1 mg/kg naloxone s.c. 2 h after the last drug administration. As shown in Fig. 3, vehicle-treated mice exhibited no platform jumping behavior, whereas morphine-treated mice all exhibited platform jumping, indicating development of morphine dependence. The concurrent administration of 9 -THC with morphine for 7 days significantly reduced the number of mice showing platform jumping by 50%. However, the occurrence of platform jumping was not completely prevented by the daily administration of 9 -THC. Interestingly, naloxone-induced diarrhea was significantly increased in the morphine group treated daily with 9 -THC (Fig. 4). Although locomotor activity was not directly measured in this study, we did not observe any distinct differences between any of the treat- Fig. 4. Effects of 9 -THC on naloxone-precipitated morphine withdrawal diarrhea. Mice were treated chronically with either distilled water vehicle, morphine (200 mg/kg p.o., days 1 2; 300 mg/kg p.o., days 3 7), or morphine plus 20 mg/kg 9 -THC p.o. twice daily for 7 days. Naloxone (1 mg/kg s.c.) was injected 2 h after the last drug administration, and the mice were immediately placed on platforms and observed for 10 min. Results are presented as the percentage of mice in each group of six that exhibited diarrhea., significantly different from vehicle-treated group (p 0.05), ANOVA and Tukey-Kramer post hoc test. ment groups during the 10-min period on the jumping platforms. Effects of Acute 9 -THC on the Reversal of Morphine Tolerance. The purpose of this experiment was to determine
4 Modulation of Morphine Tolerance and Dependence by 9 -THC 815 the antinociceptive efficacy of 9 -THC or combinations of 9 -THC and morphine after the development of morphine tolerance. Mice received distilled water vehicle or morphine twice daily for 7 days according to the above paradigms. On the test day, mice received vehicle (1:1:18) or various doses of 9 -THC p.o. 12 h after the last morphine administration and were tested for antinociception 30 min later in the tail-flick test. In vehicle-treated mice, 9 -THC produced a dose-response relationship, with the 1 mg/kg dose producing a low degree of antinociception similar to vehicle, whereas the 50 mg/kg dose produced significant antinociception (Fig. 5). Morphine-tolerant mice showed a much greater antinociceptive response to lower doses of 9 -THC than did their vehicletreated counterparts, suggesting that morphine-tolerant mice were more sensitive to 9 -THC-induced antinociception and were not cross-tolerant to 9 -THC. A dose of 50 mg/kg 9 -THC was equally effective in vehicle-treated and morphine-tolerant mice. Effect of Acute 9 -THC on the Expression of Physical Dependence on Morphine. To determine whether 9 -THC could prevent the expression of naloxone-precipitated morphine withdrawal signs, we administered vehicle (1:1:18) or various doses of 9 -THC to chronic vehicle-treated and morphine-treated mice 12 h after their last vehicle or morphine administration. A 1 mg/kg s.c. dose of naloxone was injected 2 h after 9 -THC, and mice were observed for 10 min for jumping and diarrhea. All doses of 9 -THC tested reduced naloxone-precipitated platform jumping behavior in morphine-dependent mice by 50% (Fig. 6). However, there were still a significant number of morphine-treated animals exhibiting jumping as compared with vehicle-treated animals. There were no differences in naloxone-precipitated diarrhea among these groups (data not shown). Again, no differences in locomotor activity were observed. Discussion There are several similarities in the pharmacology of 9 - THC and morphine, and it has been shown that an interaction exists between cannabinoid and opioid pathways. Our Fig. 5. Effects of acutely administered 9 -THC p.o. in vehicle-treated and morphine-tolerant mice. Mice were administered distilled water vehicle or morphine (200 mg/kg p.o., days 1 2; 300 mg/kg p.o., days 3 7) twice daily for 7 days. At 12 h after the last drug treatment, 9 -THC p.o. or vehicle (1:1:18) p.o. was administered, and the mice were tested 30 min later in the tail-flick test. Data are presented as mean S.E.M. with six mice per group., significantly different from corresponding vehicletreated group (p 0.05). $, significantly different from vehicle-treated/ vehicle-tested group (p 0.05). #, significantly different from morphinetreated/vehicle-tested group (p 0.05), ANOVA and Tukey-Kramer post hoc test. Fig. 6. Effects of acutely administered 9 -THC on naloxone-precipitated morphine withdrawal platform jumping. Mice were treated chronically with either distilled water vehicle or morphine (200 mg/kg p.o., days 1 2; 300 mg/kg p.o., days 3 7) p.o. twice daily for 7 days. At 12 h after the last drug administration, vehicle (1:1:18) or 9 -THC p.o. was administered. Naloxone (1 mg/kg s.c.) was injected 2 h later, and the mice were immediately placed on platforms and observed for 10 min. Results are presented as the percentage of mice in each group of six that jumped from the platform., significantly different from corresponding vehicle-treated group (p 0.05). #, significantly different from morphine-treated/vehicletested group (p 0.05), ANOVA and Tukey-Kramer post hoc test. aim was to investigate the effects of acute and repetitive oral treatment with the cannabinoid 9 -THC on the expression of tolerance to and physical dependence on morphine. We show that cotreatment of mice with a low dose of 9 -THC prevents the development of morphine tolerance and attenuates the level of physical dependence as measured by withdrawal jumping and diarrhea. These results support an interaction between endogenous cannabinoid and opioid systems. It was important for us to explore the oral route of administration, since both 9 -THC and morphine are administered orally in clinics. The data presented here are the first report of the prevention of morphine tolerance by a low oral dose of 9 - THC. Morphine tolerance has been demonstrated in many different models (Way et al., 1969; Huidobro et al., 1976). Cellular events that occur in morphine tolerance include desensitization of the -opioid receptor and a reduction in -opioid agonist potency (Yoburn et al., 1993; Bernstein and Welch, 1998). The development of tolerance to morphine is also consistent with down-regulation of the -opioid receptor at spinal and supraspinal sites (Bernstein and Welch, 1998; Cichewicz et al., 2001). However, observation of receptor down-regulation is highly variable with in vivo studies. We hypothesized that replacing morphine treatment with combination 9 -THC/morphine treatment would prevent morphine antinociceptive tolerance. Our data support that hypothesis, since after a 7-day treatment with both morphine and 9 -THC, no antinociceptive tolerance to morphine occurred. At the highest challenge dose of morphine, there was a trend for the combination-treated curve to resemble the morphine-tolerant curve. Yet, statistically, the ED 50 values of these two curves were different. The mechanism by which 9 -THC prevents morphine tolerance at low doses but not high doses has yet to be defined. However, it seems logical that the two drugs together might yield an increase, not a decrease, in the likelihood of tolerance development, due to enhancement of morphine-induced antinociception by 9 -THC and a potential for greater-than-normal stimulation of opioid receptors by 9 -THC-induced release of endogenous
5 816 Cichewicz and Welch opioids (Smith et al., 1994; Pugh et al., 1996). Since morphine tolerance is associated with desensitization of -opioid receptors (for review, see Williams et al., 2001), it is possible that 9 -THC enhances the efficacy of G-protein coupling to -receptors and thus prevents desensitization. Corchero et al. (1999) report that administration of 9 -THC for 1, 3, 7, or 14 days causes an increase in DAMGO-stimulated guanosine 5 -O-(3-[ 35 S]thio)triphosphate binding in the caudate-putamen, supporting the theory that 9 -THC increases opioid receptor/transduction coupling. The RAVE theory (relative activity versus endocytosis) by Whistler et al. (1999) suggests that morphine, although a high-efficacy agonist, has little ability to induce endocytosis of -opioid receptors that would attenuate prolonged signaling by chronic administration of morphine. However, in combination with DAMGO, an enkephalin derivative, cells containing morphine-bound receptors showed profound endocytosis (He et al., 2002). Therefore, in our combination treatment, endogenous opioids released by 9 -THC may enhance morphine s ability to endocytose and recycle its receptors, thus reducing the development of tolerance. The argument that an increase in 9 - THC-induced analgesia over 7 days may contribute to the reduction in morphine tolerance can be countered by the fact that there is no analgesic response at the lowest challenge dose of morphine, indicating that neither morphine nor 9 - THC is contributing to provide analgesia. Further work with receptor antagonists may elucidate these mechanisms. Other possibilities in defining the role of 9 -THC in prevention of morphine tolerance involve second-messenger systems. Acute administration of morphine decreases adenylyl cyclase activity, thus reducing intracellular levels of camp, whereas chronic morphine causes an up-regulation of adenylyl cyclase activity (Sharma et al., 1975). In morphine withdrawal, an increase in neurotransmitter release is initiated through a camp-dependent mechanism (Valverde et al., 1996; Williams et al., 2001), and so camp levels remain elevated. Since acute 9 -THC has been shown to reduce camp, it may be possible that 9 -THC acts in opposition to morphine to maintain basal camp levels, thus preventing tolerance to morphine. NMDA receptor activation has also been implicated in the development of morphine tolerance and dependence (for review, see Mao, 1999). NMDA receptor antagonists such as MK-801 and dextromethorphan have been effective in preventing tolerance to and dependence on morphine. It is possible that 9 -THC may have actions similar to those of NMDA antagonists. The potency of acute 9 -THC is greatly increased in morphine-tolerant mice, indicating that these mice are more sensitive to the cannabinoid s antinociceptive effects and do not become tolerant to 9 -THC, in contrast to previous reports in which morphine-pelleted mice demonstrated a significant decrease in the analgesic effects of 9 -THC i.p. (Thorat and Bhargava, 1994). These two studies differ in the route of administration of drugs and mouse strain, as well as length of drug administration. However, others report that antinociceptive effects of 9 -THC are potentiated in morphine-dependent rats (Rubino et al., 1997). It is possible that the induction of oral morphine tolerance causes an alteration in the CB1 system, increasing the potency of 9 -THC. These results suggest that effective antinociception can be produced in morphine-tolerant subjects utilizing 20 mg/kg 9 -THC. Combination therapy reduces not only morphine tolerance, but dependence as well. A 20 mg/kg p.o. dose of 9 -THC administered for 7 days with morphine reduced naloxoneprecipitated platform jumping by 50%. Previous studies show that repetitive pretreatment with 9 -THC in mice treated chronically with morphine significantly reduces naloxoneprecipitated withdrawal signs (Valverde et al., 2001). Morphine withdrawal is associated with decreased dopamine levels in various brain regions associated with reward such as the ventral tegmental area and nucleus accumbens (Tokuyama et al., 2000; Walters et al., 2000). 9 -THC may be reducing the severity of morphine withdrawal by increasing dopamine levels in these areas (Melis et al., 2000). However, reports have shown that chronic administration of SR A, the CB1 antagonist, also lessens several morphine withdrawal symptoms (Mas-Nieto et al., 2001). These authors hypothesize that stabilization of CB1 receptors upon antagonist binding may sequester a pool of G i/o -proteins away from -opioid receptors, thus reducing the development of dependence to morphine. 9 -THC may serve the same function by usurping signaling pathways utilized by morphine to produce dependence at -receptors. These data, in which both an agonist and an antagonist at the CB1 receptor reduce the signs of morphine withdrawal, support an interaction between endogenous opioid and cannabinoid systems. However, we can conclude that there is a clear separation of morphine tolerance and physical dependence, since 9 -THC was able to completely prevent morphine tolerance but only partially reduced signs of morphine withdrawal. Only 20% of morphine-tolerant mice exhibited diarrhea upon injection of naloxone. Furthermore, mice that received 9 -THC daily with morphine for 7 days exhibited an increased occurrence of diarrhea upon naloxone injection. However, Lichtman et al. (2001) report that a 1 mg/kg s.c. dose of naloxone precipitates diarrhea in all morphine-tolerant mice tested. The reason for the increase in naloxone-precipitated diarrhea in combination-treated mice is unclear; however, it may be that diarrhea is not as reliable as platform jumping to measure morphine withdrawal. Studies using the cannabinoid antagonist SR A would further help to elucidate the role of 9 -THC in the production of diarrhea in these mice. Our results agree with previous reports that acute administration of 9 -THC and other cannabinoids also decreases naloxone-precipitated jumping in morphine-dependent rodents (Hine et al., 1975; Bhargava, 1976). Yamaguchi et al. (2001) suggest that the appearance of withdrawal signs in morphine-dependent mice results from an inactivation of CB1 receptors and/or the inhibition of release or synthesis of endocannabinoids. Thus, during morphine dependence, the endocannabinoid system may be activated, whereas withdrawal may inactivate the system. The acute administration of 9 -THC prior to precipitation of morphine withdrawal by naloxone may prevent inactivation of the endocannabinoid system by providing an alternate way of stimulating CB1 receptors. However, others have failed to ameliorate jumping with acute 9 -THC (Lichtman et al., 2001). Differences in naloxone dose may account for the disparity. The dose of naloxone used in the present studies (1 mg/kg s.c.) has consistently been shown to precipitate morphine withdrawal symptoms (Campbell et al., 2000; Mas-Nieto et al., 2001). Other researchers have used heroic doses of naloxone up to 50 mg/kg s.c., far beyond the selectivity of antagonizing
6 Modulation of Morphine Tolerance and Dependence by 9 -THC 817 -opioid receptors, and could clearly result in discrepancies from our results. In summary, we have presented the first evidence that oral morphine tolerance can be prevented by coadministration of a low dose of oral 9 -THC. This dose of 9 -THC, although inactive on its own, is also sufficient to reduce the naloxoneprecipitated morphine withdrawal sign of platform jumping in mice. The clinical implication of this work is the possibility that 9 -THC and morphine in combination therapy may be more effective analgesics for a longer period of time than morphine alone, without tolerance to subsequent opioid treatments. In addition, the potential cross-talk between cannabinoid and opioid systems in the development of morphine dependence may indicate new strategies for treatment of opioid addiction. References Bernstein MA and Welch SP (1998) Mu opioid receptor downregulation and campdependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res 55: Bhargava HN (1976) Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology 49: Bhargava HN (1978) Quantitation of morphine tolerance induced by pellet implantation in the rat. J Pharm Pharmacol 30: Campbell VC, Dewey WL, and Welch SP (2000) Comparison of [3H]Glyburide binding with opiate analgesia, tolerance and dependence in ICR and Swiss-Webster mice. J Pharmacol Exp Ther 295: Cicero TJ and Meyer ER (1973) Morphine pellet implantation in rats: quantitative assessment of tolerance and dependence. J Pharmacol Exp Ther 184: Cichewicz DL, Haller VL, and Welch SP (2001) Changes in opioid and cannabinoid receptor protein following short-term combination treatment with 9 -tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 297:1 7. Cichewicz DL, Martin ZL, Smith FL, and Welch SP (1999) Enhancement of opioid antinociception by oral 9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 289: Corchero J, Romero J, Berrendero F, Fernandez-Ruiz J, Ramos JA, Fuentes JA, and Manzanares J (1999) Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 67: D Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacologie 72: Ellison NM (1993) Opioid analgesics for cancer pain: toxicities and their treatments, in Cancer Pain (Patt RB ed) pp , JB Lippincott, Philadelphia. Harris LS and Pierson AK (1964) Some narcotic antagonists in the benzomorphan series. J Pharmacol Exp Ther 143: He L, Fong J, von Zastrow M, and Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108: Hine B, Friedman E, Torrelio M, and Gershon S (1975) Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science (Wash DC) 187: Huidobro F, Huidobro-Toro JP, and Leong Way E (1976) Studies on tolerance development to single doses of morphine in mice. J Pharmacol Exp Ther 198: Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (Wash DC) 283: Lichtman AH, Sheikh SM, Loh HH, and Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in 9 -tetrahydrocannabinol and morphinedependent mice. J Pharmacol Exp Ther 298: Mao J (1999) NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev 30: Mao J, Price DD, Caruso FS, and Mayer DJ (1996) Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain 67: Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, and Noble F (2001) Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132: Melis M, Gessa GL, and Diana M (2000) Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24: Navarro M, Chowen J, Carrera MRA, del Arco I, Villanua MA, Martin Y, Roberts AJ, Koob GF, and Rodriguez de Fonseca F (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9: Pugh G, Smith PB, Dombrowski DS, and Welch SP (1996) The role of endogenous opioids in enhancing the antinociception produced by the combination of 9 - tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 279: Rubino T, Tizzoni L, Vigano D, Massi P, and Parolaro D (1997) Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 8: Sharma SK, Klee WA, and Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72: Smith FL, Cichewicz D, Martin ZL, and Welch SP (1998) The enhancement of morphine antinociception by 9-tetrahydrocannabinol. Pharmacol Biochem Behav 60: Smith PB, Welch SP, and Martin BR (1994) Interactions between 9 -tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268: Tallarida RJ and Murray RB (1987) Procedures 5 and 8, in Manual of Pharmacologic Calculations With Computer Programs, pp16 18, Springer-Verlag, New York. Thorat SN and Bhargava HN (1994) Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260:5 13. Tokuyama S, Ho IK, and Yamamoto T (2000) A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Brain Res Bull 52: Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, and Roques BP (2001) Delta 9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13: Valverde O, Tzavar E, Hanoune J, Roques BP, and Maldonado R (1996) Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. Eur J Neurosci 8: Vela G, Ruiz-Gayo M, and Fuentes JA (1995) Anandamide decreases naloxoneprecipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34: Walters CL, Aston-Jones G, and Druhan JP (2000) Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist. Neuropsychopharmacology 23: Way EL, Loh HH, and Shen F (1969) Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167:1 8. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: Williams JT, Christie MJ, and Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81: Yamaguchi T, Hagiwara Y, Tanaka H, Sugiyura T, Waku K, Shoyama Y, Watanabe S, and Yamamoto T (2001) Endogenous cannabinoid, 2-arachidonylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909: Yoburn BC, Billings B, and Duttaroy A (1993) Opioid receptor regulation in mice. J Pharmacol Exp Ther 265: Address correspondence to: Dr. Sandra P. Welch, P.O. Box , MCV Station, Richmond, VA Swelch@hsc.vcu.edu
Antinociceptive Synergy between 9 -Tetrahydrocannabinol and Opioids after Oral Administration
0022-3565/03/3043-1010 1015$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 304, No. 3 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 45575/1042482
More informationOpioid and Cannabinoid Modulation of Precipitated Withdrawal in 9 -Tetrahydrocannabinol and Morphine-Dependent Mice
0022-3565/01/2983-1007 1014$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 298, No. 3 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3812/923555
More informationTime course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by Δ 9 -tetrahydrocannabinol
European Journal of Pharmacology 539 (2006) 57 63 www.elsevier.com/locate/ejphar Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by Δ 9 -tetrahydrocannabinol
More informationPrevention of Development of Tolerance and Dependence to Opiate in Mice by BR-16A (Mentat) A Herbal Psychotropic Preparation
[Indian Journal of Experimental Biology (1992): (30), 885] Prevention of Development of Tolerance and Dependence to Opiate in Mice by BR-16A (Mentat) A Herbal Psychotropic Preparation Kulkarni, S.K. and
More informationNMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S7 Proceedings Supplement NDMA-Receptor Antagonists: Evolving Role in Analgesia NMDA-Receptor Antagonists and Opioid Receptor Interactions
More informationBrief Communication. The Journal of Neuroscience, March 23, (12):
The Journal of Neuroscience, March 23, 2005 25(12):3229 3233 3229 Brief Communication In Vivo Activation of a Mutant -Opioid Receptor by Naltrexone Produces a Potent Analgesic Effect But No Tolerance:
More informationAbsence of -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice
The Journal of Neuroscience, December 1, 2001, 21(23):9499 9505 Absence of -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice Andreas Zimmer, 1,2 Emmanuel Valjent, 3 Monika König, 1
More informationMOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre
1 MOLECULAR BIOLOGY OF DRUG ADDICTION Sylvane Desrivières, SGDP Centre Reward 2 Humans, as well as other organisms engage in behaviours that are rewarding The pleasurable feelings provide positive reinforcement
More informationSynergistic interactions between cannabinoid and opioid analgesics
Life Sciences 74 (2004) 1317 1324 www.elsevier.com/locate/lifescie Current Topics Synergistic interactions between cannabinoid and opioid analgesics Diana L. Cichewicz* Department of Pharmacology and Toxicology,
More informationCB1 Receptor Antagonist Precipitates Withdrawal in Mice Exposed to 9 -Tetrahydrocannabinol 1
0022-3565/98/2853-1150$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 285, No. 3 Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationUltra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats
Psychopharmacology (2005) 181: 576 581 DOI 10.1007/s00213-005-0022-7 ORIGINAL INVESTIGATION Mary C. Olmstead. Lindsay H. Burns Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive
More informationTRAMADOL, A CENTRALLY ACTING OPIOID : ANTICONVULSANT EFFECT AGAINST MAXIMAL ELECTROSHOCK SEIZURE IN MICE
Indian J Physiol Pharmacol 1998; 42 (3) : 407-411 TRAMADOL, A CENTRALLY ACTING OPIOID : ANTICONVULSANT EFFECT AGAINST MAXIMAL ELECTROSHOCK SEIZURE IN MICE ANSHU MANOCHA, KRISHNA K. SHARMA* AND PRAMOD K.
More informationAnalgesics, pain and tolerance: The St John s discussion
EDITORIAL Analgesics, pain and tolerance: The St John s discussion Four of the articles in the present issue of Pain Research & Management discuss preclinical issues relevant to understanding the changes
More informationLow dose combination of morphine and Δ 9 -tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors
European Journal of Pharmacology 571 (2007) 129 137 www.elsevier.com/locate/ejphar Low dose combination of morphine and Δ 9 -tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization
More informationSex Differences in Cannabinoid 1 vs. Cannabinoid 2 Receptor- Selective Antagonism of Antinociception Produced by
1521-0103/12/3403-787 800$25.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 340, No. 3 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 188540/3752074
More informationAbuse Potential of Morphine/ Dextromethorphan Combinations
S26 Journal of Pain and Symptom Management Vol. 19 No. 1(Suppl.) January 2000 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia Abuse Potential of Morphine/ Dextromethorphan
More informationFrom opium to analgesic tests: An introduction to the functioning and studying of the opioid system
Practice-oriented, student-friendly modernization of the biomedical education for strengthening the international competitiveness of the rural Hungarian universities TÁMOP-4.1.1.C-13/1/KONV-2014-0001 From
More informationRole of camp-dependent Protein Kinase (PKA) in Opioid Agonist-Induced -Opioid Receptor Downregulation and Tolerance in Mice
SYNAPSE 38:322 327 (2000) Role of camp-dependent Protein Kinase (PKA) in Opioid Agonist-Induced -Opioid Receptor Downregulation and Tolerance in Mice JI SHEN, A. BENEDICT GOMES, ANNEMARIE GALLAGHER, KRISTI
More informationLocal administration of 9 -tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action
Psychopharmacology (1999) 143:322 326 Springer-Verlag 1999 RAPID COMMUNICATION Mei-Chuan Ko James H. Woods Local administration of 9 -tetrahydrocannabinol attenuates capsaicin-induced thermal nociception
More informationFrom opium to analgesic tests: An introduction to the functioning and studying of the opioid system
Practice-oriented, student-friendly modernization of the biomedical education for strengthening the international competitiveness of the rural Hungarian universities TÁMOP-4.1.1.C-13/1/KONV-2014-0001 From
More informationBuprenorphine Blocks - and -Opioid Receptor-Mediated Antinociception in the Mouse
0022-3565/03/3061-394 400$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 306, No. 1 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 48835/1076304
More informationNIH Public Access Author Manuscript Neuropharmacology. Author manuscript; available in PMC 2009 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Neuropharmacology. 2008 December ; 55(7): 1219 1225. doi:10.1016/j.neuropharm.2008.07.038. Repeated Cannabinoid Injections into the
More informationThe opioid- Sparing Effect of Cannabinoids. Janel Gracey, MD, AAPM, ICSAM
The opioid- Sparing Effect of Cannabinoids Janel Gracey, MD, AAPM, ICSAM Disclosures None Marijuana, Cannabis THC, the other white meat Opioid crisis, Canadian Pain Society, overdoses, etc. Is Cannabis
More informationDifferential Blockade of the Antinociceptive Effects of Centrally Administered Cannabinoids by SR141716A 1
0022-3565/98/2863-1301$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 286, No. 3 Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationAction Potentials and Synaptic Transmission. BIO 219 Napa Valley College Dr. Adam Ross
Action Potentials and Synaptic Transmission BIO 219 Napa Valley College Dr. Adam Ross Review of action potentials Nodes of Ranvier Nucleus Dendrites Cell body In saltatory conduction, the nerve impulses
More informationRecent Advances in Energy, Environment, Biology and Ecology
Acute and long-term effects elicited by psychoactive drugs on 50-kHz ultrasonic vocalizations in rats: development of a new experimental tool for the study of drug-mediated reward NICOLA SIMOLA Department
More informationRimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats
Psychopharmacology (2008) 198:461 466 DOI 10.1007/s00213-007-0913-x ORIGINAL INVESTIGATION Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats John E.
More informationAM281, Cannabinoid Antagonist/Inverse agonist, Ameliorates Scopolamine- Induced Cognitive Deficit
Iranian Journal of Basic Medical Sciences Vol. 15, No. 5, Sep-Oct 2012, 1106-1110 Received: May 28, 2011; Accepted: Dec 24, 2011 www.mums.ac.ir Short Communication AM281, Cannabinoid Antagonist/Inverse
More informationProtective Effect of Mentat (BR-16A) A Herbal Preparation, on Alcohol Abstinence-Induced Anxiety and Convulsions
[Indian Journal of Experimental Biology (1993): (31), 435] Protective Effect of Mentat (BR-16A) A Herbal Preparation, on Alcohol Abstinence-Induced Anxiety and Convulsions Kulkarni, S.K. and Anita Verma,
More informationAgonists at mu opioid receptors spin the wheels to keep the action going.
Molecular Pharmacology This article has Fast not been Forward. copyedited Published and formatted. on The October final version 20, may 2004 differ as from doi:10.1124/mol.104.008433 this version. Agonists
More informationD. Nishizawa 1, N. Gajya 2 and K. Ikeda 1, * Global Research & Development, Nagoya Laboratories, Pfizer Japan Inc, Nagoya, Japan
Current Neuropharmacology, 2011, 9, 113-117 113 Identification of Selective Agonists and Antagonists to G Protein-Activated Inwardly Rectifying Potassium Channels: Candidate Medicines for Drug Dependence
More informationBehavioral Activation Induced by D 2 -Like Receptor Stimulation during Opiate Withdrawal 1
0022-3565/00/2942-0531$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 294, No. 2 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationMorphine analgesic tolerance in 129P3/J and 129S6/SvEv mice
Pharmacology, Biochemistry and Behavior 85 (2006) 769 779 www.elsevier.com/locate/pharmbiochembeh Morphine analgesic tolerance in 129P3/J and 129S6/SvEv mice Camron D. Bryant a,b,c,, Kristofer W. Roberts
More informationInvolvement of the endocannabinoid system in drug addiction
Review TRENDS in Neurosciences Vol.29 No.4 April 2006 Involvement of the endocannabinoid system in drug addiction Rafael Maldonado, Olga Valverde and Fernando Berrendero Laboratori de Neurofarmacologia,
More informationBasic and Clinical Spring 2012, Volume 3, Number 3
The Effect of Nicotine Administration on Physical and Psychological Signs of Withdrawal Syndrome Induced by Single or Frequent Doses of Morphine in Rats Ahmad Taghavi Rafsanjani 1, Abbas Haghparast 2,
More informationNeurotransmitter Systems II Receptors. Reading: BCP Chapter 6
Neurotransmitter Systems II Receptors Reading: BCP Chapter 6 Neurotransmitter Systems Normal function of the human brain requires an orderly set of chemical reactions. Some of the most important chemical
More informationConstitutively Active Mu Opioid Receptors Mediate the Enhanced Conditioned Aversive Effect of Naloxone in Morphine-Dependent Mice
(2006) 31, 171 177 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Constitutively Active Mu Opioid Receptors Mediate the Enhanced Conditioned Aversive
More informationNon-opioidergic mechanism mediating morphine-induced. antianalgesia in the mouse spinal cord. Hsiang-En Wu, Jonathan Thompson, Han-Sen Sun,
JPET This Fast article Forward. has not been Published copyedited on and formatted. March 3, The 2004 final version as DOI:10.1124/jpet.104.065334 may differ from this version. JPET #65334 Non-opioidergic
More informationPharmacological characterization of buprenorphine, a mixed agonist antagonist with k analgesia
Brain Research 744 1997 41 46 Research report Pharmacological characterization of buprenorphine, a mixed agonist antagonist with k analgesia Chaim G. Pick a,), Yakov Peter a, Shaul Schreiber b, Ronit Weizman
More informationNeurophysiology and Neurochemistry in PsychoGeriatrics
Tel Aviv University Sackler Faculty of Medicine CME in Psychiatry Neurophysiology and Neurochemistry in PsychoGeriatrics Nicola Maggio, MD, PhD Sackler Faculty of Medicine Tel Aviv University Department
More informationPsychotropic Drugs in the Pipeline. Norman Sussman, M.D. Professor of Psychiatry New York University School of Medicine
Psychotropic Drugs in the Pipeline Norman Sussman, M.D. Professor of Psychiatry New York University School of Medicine Norman Sussman, MD No Conflict of Interest to Declare Antidepressant Pipeline We need
More informationThe Neuroscience of Addiction: A mini-review
The Neuroscience of Addiction: A mini-review Jim Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital Disclosures Neither I nor my spouse/partner has a relevant financial relationship
More informationPretreatment with midazolam suppresses morphine withdrawal response in mice and rats
685 2002, Acta Pharmacologica Sinica ISSN 1671-4083 Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com Pretreatment with midazolam suppresses morphine withdrawal
More informationMedical Cannabinoids for the Management of Chronic Noncancer Pain
Medical Cannabinoids for the Management of Chronic Noncancer Pain Dr Mark A. Ware MBBS MSc McGill University 12 June 2018 Disclosures Grants: CanniMed Consulting: CHI Inc Emmes 1 Canadian Consortium for
More informationIntroduction SHORT COMMUNICATION. Irma V. Belozertseva Anton Yu. Bespalov
Naunyn-Schmiedeberg s Arch Pharmacol (1998) 358:270 274 Springer-Verlag 1998 SHORT COMMUNICATION Irma V. Belozertseva Anton Yu. Bespalov Effects of NMDA receptor channel blockers, dizocilpine and memantine,
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationOverview of Pharmacodynamics. Psyc 472 Pharmacology of Psychoactive Drugs. Pharmacodynamics. Effects on Target Binding Site.
Pharmacodynamics Overview of Pharmacodynamics Psychology 472: Pharmacology of Psychoactive Drugs Generally is defined as effects of drugs on a systems Can be associated with any system Neural, Heart, Liver,
More informationSelectivity of Delta and Kappa Opioid Ligands Depends on the Route of Central. Administration in Mice. Mary M. Lunzer and Philip S.
JPET Fast This article Forward. has not been Published copyedited on and March formatted. 30, The 2007 final version as DOI:10.1124/jpet.107.120279 may differ from this version. Title Page Selectivity
More informationTHE OPIUM POPPY OPIOID PHARMACOLOGY 2/18/16. PCTH 300/305 Andrew Horne, PhD MEDC 309. Papaver somniferum. Poppy Seeds Opiates
OPIOID PHARMACOLOGY PCTH 300/305 Andrew Horne, PhD andrew.horne@ubc.ca MEDC 309 THE OPIUM POPPY Papaver somniferum Sleep-bringing poppy Poppy Seeds Opiates Opium Poppy Straw 1 OPIATES VS. OPIOIDS Opiates:
More informationRepeated stress exposure causes strain-dependent shifts in the behavioral economics of cocaine in rats
bs_bs_banneraddiction Biology PRECLINICAL STUDY doi:10.1111/adb.12123 Repeated stress exposure causes strain-dependent shifts in the behavioral economics of cocaine in rats Peter A. Groblewski 1, Chad
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationmorphine-dependence and tolerance in the rat
British Journal of Pharmacology (1996) 11, 1-15 1996 Stockton Press All rights reserved 7-11/96 $12. Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the
More informationMorphine and most other opioid drugs are widely used
Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action Kyoung-Shim Kim*, Ko-Woon Lee*, Kang-Woo Lee*, Joo-Young Im*, Ji Yeoun Yoo*, Seung-Woo Kim, Ja-Kyeong Lee, Eric J. Nestler, and
More informationDrug Receptor Interactions and Pharmacodynamics
Drug Receptor Interactions and Pharmacodynamics Dr. Raz Mohammed MSc Pharmacology School of Pharmacy 22.10.2017 Lec 6 Pharmacodynamics definition Pharmacodynamics describes the actions of a drug on the
More informationMk-801 Administration in Adolescent Male Rats and Cocaine Conditioned Place
Mk-801 Administration in Adolescent Male Rats and Cocaine Conditioned Place Preference Stephanie Willis, Jonnique Adjmul, Shabaaz Sandhu, Antoniette M. Maldonado-Devincci, Cheryl Kirsten ABSTRACT The present
More informationUnderstanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO
Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year
More informationAlternatively spliced mu opioid receptor C termini impact the diverse actions of morphine
Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine Jin Xu,, Gavril W. Pasternak, Ying-Xian Pan J Clin Invest. 2017;127(4):1561-1573. https://doi.org/10.1172/jci88760.
More informationEffects of Alprazolam and Fluoxetine on Morphine Sensitization in Mice
Physiol. Res. 51: 417-423, 2002 Effects of Alprazolam and Fluoxetine on Sensitization in Mice M. VOTAVA, M. KRŠIAK, V. MORAVEC Department of Pharmacology, Third Faculty of Medicine, Charles University,
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(5):468-472 Study on the anticonvulsant activity of Pentazocine
More informationUniversity of Colorado-Boulder
University of Colorado-Boulder Activated Glia as Culprits in Opposing Opioid Analgesia & Driving Tolerance, Dependence & Reward: Role of a Non-classical Non-classical Opioid Receptor Linda R. Watkins Psychology
More informationGlycine-gated ion channels Converging mechanism and therapeutic potentials
Glycine-gated ion channels Converging mechanism and therapeutic potentials Li Zhang Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health,
More informationC81ADD Psychology of Addiction. Alcohol. Ethyl alcohol (ethanol) School of Psychology. Tobias Bast.
C81ADD Psychology of Addiction Alcohol Ethyl alcohol (ethanol) Tobias Bast School of Psychology tobias.bast@nottingham.ac.uk 1 Selected aspects of the psychopharmacology of alcohol (ethanol) Primary neuropharmacological
More informationOPIOID ANTINOCICEPTION AND ANTIHYPERALGESIA IN COMBINATION WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISM. Dana Elaine Daugherty
OPIOID ANTINOCICEPTION AND ANTIHYPERALGESIA IN COMBINATION WITH METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISM Dana Elaine Daugherty A thesis submitted to the faculty of the University of North Carolina at
More informationDYNORPHIN-(1-13) SUPPRESSES HEROIN WITHDRAWAL SYMPTOMS IN 6 ADDICTS
DYNORPHIN-(1-13) SUPPRESSES HEROIN WITHDRAWAL SYMPTOMS IN 6 ADDICTS H.L. WEN (Neurosurgical Unit, Kwong Wah Hospital, Tung Wah Group of Hospitals, Kowloon, Hong Kong) P. Y. C. WEN (79 Hurlingham Court,
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(5): 358-362 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationRole of D 1 /D 2. dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats. Abstract INTRODUCTION
Role of D 1 dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats Ercan Ozdemir 1 *, Ihsan Bagcivan 2, Sinan Gursoy 3 1 Department of Physiology, School of Medicine, Cumhuriyet
More informationThe effects of a new opioid analgesic, meptazinol, on the
Br. J. Pharmac. (1985), 85, 25-211 The effects of a new opioid analgesic, meptazinol, on the respiration of the conscious rat I.S. Cowlrick' & N.B. Shepperson2 Wyeth Laboratories, Huntercombe Lane South,
More informationCannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or Metabolism Enhance the Reinforcing Efficacy of Heroin in Rats
(2005) 30, 2046 2057 & 2005 Nature Publishing Group All rights reserved 0893-133X/05 $30.00 www.neuropsychopharmacology.org Cannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or
More informationVITEX AGNUS-CASTUS FRUIT EXTRACT RESTRAINS ACQUISITION AND EXPRESSION OF MORPHINE-INDUCED TOLERANCE IN MICE
April 30, 2016 Archives 2016 vol.1 127-133 VITEX AGNUS-CASTUS FRUIT EXTRACT RESTRAINS ACQUISITION AND EXPRESSION OF MORPHINE-INDUCED TOLERANCE IN MICE Saberi, M. 1* ; Chavooshi, B. 2 ; Ghorbani, M. 1 ;
More informationReduction of opioid dependence by the CB 1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction
British Journal of Pharmacology (2001) 132, 1809 ± 1816 ã 2001 Nature Publishing Group All rights reserved 0007 ± 1188/01 $15.00 Reduction of opioid dependence by the CB 1 antagonist SR141716A in mice:
More informationBasics of Pharmacology
Basics of Pharmacology Pekka Rauhala Transmed 2013 What is pharmacology? Pharmacology may be defined as the study of the effects of drugs on the function of living systems Pharmacodynamics The mechanism(s)
More information3/15/2018. Pain. Pain. Opioid Analgesics Addiction. Pain
Pain Pain Well, I guess that explains the abdominal pains. Well, I guess that explains the abdominal pains. Pain is a component of virtually all clinical strategies, and management of pain is a primary
More informationThe Abilities of Specific x -Opioid Agonists, U-50,488H and U-62,066E, to Cause Antitussive Tolerance Were Lower than That of Morphine
The Abilities of Specific x -Opioid Agonists, U-50,488H and U-62,066E, to Cause Antitussive Tolerance Were Lower than That of Morphine Junzo Kamei, Hiroaki Tanihara and Yutaka Kasuya Department of Pharmacology,
More informationZoektocht naar innovatieve geneesmiddelen voor de toekomst - Verslaving en ander gedrag in moleculair perspectief
Zoektocht naar innovatieve geneesmiddelen voor de toekomst - Verslaving en ander gedrag in moleculair perspectief Prof. dr. Chris Kruse Swammerdam Institute, UvA Solvay Pharmaceuticals Drug Discovery Assets
More informationA. Personal Statement
NAME: CHARTOFF, ELENA OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors.
More informationMarijuana and cannabinoids
Psych 181: Dr. Anagnostaras Lec 10: Marijuana Marijuana and cannabinoids Cannabis sativa, hemp One of earliest non-food plants cultivated fiber for rope, seeds for oil and birdseed 1st archaeological evidence
More informationINTRODUCTION. Neuropsychopharmacology (2010) 35, & 2010 Nature Publishing Group All rights reserved X/10 $32.00
(2010) 35, 1775 1787 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00 www.neuropsychopharmacology.org FAAH / Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor
More informationMechanism of Attenuation of Morphine Antinociception by Chronic Treatment with L-Arginine 1
0022-3565/97/2812-0707$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 281, No. 2 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationELŐADÁS KIVONAT CLASSROOM LECTURE HANDOUT. financed by the program
TÁMOP-4.1.1.C-13/1/KONV-2014-0001 projekt Az élettudományi-klinikai felsőoktatás gyakorlatorientált és hallgatóbarát korszerűsítése a vidéki képzőhelyek nemzetközi versenyképességének erősítésére program
More informationA novel role for vitamin D: modulation of expression and function of the local renin angiotensin system in mouse pancreatic islets
Diabetologia () 5:77 DOI.7/s5--- SHORT COMMUNICATION A novel role for vitamin D: modulation of expression and function of the local renin angiotensin system in mouse pancreatic islets Q. Cheng & Y. C.
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationPSY 302 Lecture 6: The Neurotransmitters (continued) September 12, 2017 Notes by: Desiree Acetylcholine (ACh) CoA + Acetate Acetyl-CoA (mitochondria) (food, vinegar) + Choline ChAT CoA + ACh (lipids, foods)
More informationThe role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice
Psychopharmacology (2008) 197:443 448 DOI 10.1007/s00213-007-1053-z ORIGINAL INVESTIGATION The role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice Paul Marquez
More informationInvolvement of CB1 cannabinoid receptors in emotional behaviour
Psychopharmacology (2002) 159:379 387 DOI 10.1007/s00213-001-0946-5 ORIGINAL INVESTIGATION Miquel Martin Catherine Ledent Marc Parmentier Rafael Maldonado Olga Valverde Involvement of CB1 cannabinoid receptors
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationCo-administration of calcium gluconate and magnesium acetate effectively blocks the signs of morphine withdrawal in mice
Magnesium Research 212; 25 (1): 4-8 ORIGINAL ARTICLE Co-administration of calcium gluconate and magnesium acetate effectively blocks the signs of morphine withdrawal in mice Mohammed Rabbani, Valiollah
More informationEFFECTS OF ACUTELY APPLIED CANNABINOID CB1 LIGANDS ON NOCICEPTION IN RATS WITH A MODEL OF DEPRESSION
ý Comptes rendus de l Académie bulgare des Sciences ÌÓÑ ÆÓ ¾¼½ MEDECINE Pathophysiologie EFFECTS OF ACUTELY APPLIED CANNABINOID CB1 LIGANDS ON NOCICEPTION IN RATS WITH A MODEL OF DEPRESSION Miroslav Marinov,
More informationDifferential effects of endocannabinoid catabolic inhibitors on opioid withdrawal in mice
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Differential effects of endocannabinoid catabolic inhibitors on opioid withdrawal in mice Thomas Gamage
More informationCannabis. Member of the Cannabaceae family of flowering plants (along with hops) Cannabis sativa (v. sativa, indica, afghanica, ruderalis)
Member of the Cannabaceae family of flowering plants (along with hops) sativa (v. sativa, indica, afghanica, ruderalis) Only females flowers contain high concentrations of psychoactive oils (cannabinoids)
More informationSynergistic interactions of endogenous opioids and cannabinoid systems 1
Ž. Brain Research 848 1 183 10 www.elsevier.comrlocaterbres Interactive report Synergistic interactions of endogenous opioids and cannabinoid systems 1 Sandra P. Welch ), Micah Eads Department of Pharmacology
More informationDopaminergic Signaling Mediates the Motivational Response Underlying the Opponent Process to Chronic but Not Acute Nicotine
(21) 35, 943 954 & 21 Nature Publishing Group All rights reserved 893-133X/1 $32. www.neuropsychopharmacology.org Dopaminergic Signaling Mediates the Motivational Response Underlying the Opponent Process
More informationA low dose of nicotine is sufficient to produce nicotine withdrawal in mice
Vol.2, No.1, 1-7 (2010) Health doi:10.4236/health.2010.21001 A low dose of nicotine is sufficient to produce nicotine withdrawal in mice Besson Morgane 1,2, Suarez Sandra 1, Changeux Jean-Pierre 1, Granon
More informationThe cannabinoid CB1 antagonist SR A differentially alters the. progressive-ratio schedules of drug self-administration in rats.
JPET Fast This article Forward. has not been Published copyedited on and March formatted. 26, The 2003 final version as DOI:10.1124/jpet.102.047928 may differ from this version. JPET #47928 The cannabinoid
More informationAbbott s TRPV1 Antagonist Program
Abbott s TRPV1 Antagonist Program Connie R. Faltynek, Ph.D. Sr. Director, Neuroscience and Pain Discovery American Pain Society Annual Meeting Basic Science Dinner Symposium May 9, 2008 Early History of
More informationReview Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis
(2017) 42, 1752 1765 2017 American College of. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org Review Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis Suzanne
More informationATTENUATION OF STRESS-INDUCED BEHAVIORAL DEFICITS BY AZADIRACHTA INDICA (NEEM): ROLE OF SEROTONIN
Pak. J. Bot., 38(1): 131-138, 26. ATTENUATION OF STRESS-INDUCED BEHAVIORAL DEFICITS BY AZADIRACHTA INDICA (NEEM): ROLE OF SEROTONIN NOREEN SAMAD, TAHIRA PARVEEN, SAIDA HAIDER AND DARAKHSHAN JABEEN HALEEM
More informationNeurotransmitter Functioning In Major Depressive Disorder
Neurotransmitter Functioning In Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January
More informationAnalgesic Activity of Sathikkai Podi- a Siddha Drug
Research Article Analgesic Activity of Sathikkai Podi- a Siddha Drug K. Kanagavalli 1, P. Kavitha 2, J. Anbu 3, P. Sathiya Rajeswaran 4 and P. Parthiban 5 1 UG Maruthuvam Department. 2 PG Scholar final
More informationDrugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major types
More information